Autozone Inc vs Eli Lilly And Co — how do they compare? Autozone Inc trades at $3,019.81 (market cap $49.50B), while Eli Lilly And Co trades at $1,151.98 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 20.8× Autozone Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.
| AZO | LLY | |
|---|---|---|
Market Cap | $49.50B | $1.03T |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $1.24K |
52-Week Low | $2.94K | $625.65 |
Enterprise Value | $61.88B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,078.98, up 0.21% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q3 2025, with revenue growing to $18.94B in 2025. Analyst sentiment remains strongly positive with a 72.73% buy rating and a consensus price target of $3,740, though recent news highlights stock volatility and competitive pressures.
The outlook for AZO is supported by solid fundamentals, including a 12.4% net income margin and aggressive share buybacks, but risks include slowing profit margin trends and bearish technical indicators. Upside potential exists if the company meets Q2 2026 EPS expectations of 54.51, though investors should monitor same-store sales growth and international expansion execution.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →